Our Products & Pipeline
Creating the medicines that patients need.
We’re committed to health care for all. That’s why we have a range of biosimilar drugs in our U.S. portfolio,1,2 to ultimately help more patients.
See Stimufend (pegfilgrastim-fpgk) full Prescribing Information.
See Idacio (adalimumab-aacf) full Prescribing Information.
Currently, we’re developing biosimilar medicines for oncology and immunology, plus multiple delivery systems, expected at a steady rate across the next 5+ years. Being committed to the future of biosimilars means we’re always thinking ahead.
Idacio® is not commercially available before July, 2023.
*Products pending FDA Approval. The safety or effectiveness of the products has not been established.
1. https://biosimilars.fresenius-kabi.com/products [Accessed 5.May.2022].
2. Fresenius Factsheet FY/21. https://annualreport.fresenius.com/2021/downloads. Accessed August 26, 2022.
Advanced science, manufacturing and support for biosimilars